Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trametinib - Novartis

Drug Profile

Trametinib - Novartis

Alternative Names: 1120212; GSK-1120212; GSK-1120212B; JTP-74057; Mecinist; Mekinist; Mekinisuto; TMT 212; Trametinib dimethyl sulfoxide; Trametinib DMSO

Latest Information Update: 06 Aug 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Japan Tobacco
  • Developer Amgen; Dana-Farber Cancer Institute; GlaxoSmithKline; Japan Tobacco; M. D. Anderson Cancer Center; Merck Sharp & Dohme; National Cancer Institute (USA); Novartis; Pfizer; University of Texas M. D. Anderson Cancer Center
  • Class 2 ring heterocyclic compounds; Amides; Antineoplastics; Cyclopropanes; Fluorobenzenes; Iodobenzenes; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Thyroid cancer; Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma; Non-small cell lung cancer
  • Registered Thyroid cancer
  • Phase II Acral lentiginous melanoma; Acute myeloid leukaemia; Biliary cancer; Brain metastases; Breast cancer; Cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Glioma; Multiple myeloma; Myeloid leukaemia; Pancreatic cancer; Uveal melanoma
  • Phase I/II Solid tumours
  • No development reported Leukaemia; Lymphoma; Mesothelioma
  • Discontinued Inflammation

Most Recent Events

  • 28 Jul 2020 Novartis initiates Managed Access Programme for Malignant melanoma (Combination therapy, Monotherapy, Metastatic disease) (NCT04489433)
  • 22 Jul 2020 Phase-I clinical trials in Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease) in Germany (PO) (NCT04294160)
  • 07 Jul 2020 Novartis terminates a phase Ib trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in Australia, Belgium, Canada, Netherlands and Spain and USA (PO) (NCT02703571)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top